This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
NanoString Technologies Inkomsten in het verleden
Verleden criteriumcontroles 0/6
NanoString Technologies's earnings have been declining at an average annual rate of -21.6%, while the Life Sciences industry saw earnings growing at 26.1% annually. Revenues have been growing at an average rate of 6% per year.
Belangrijke informatie
-21.6%
Groei van de winst
-10.1%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 12.9% |
| Inkomstengroei | 6.0% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -102.4% |
| Laatste winstupdate | 30 Sep 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe NanoString Technologies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 23 | 162 | -166 | 156 | 65 |
| 30 Jun 23 | 144 | -166 | 153 | 65 |
| 31 Mar 23 | 132 | -161 | 150 | 64 |
| 31 Dec 22 | 127 | -160 | 149 | 65 |
| 30 Sep 22 | 135 | -145 | 143 | 65 |
| 30 Jun 22 | 143 | -139 | 140 | 67 |
| 31 Mar 22 | 145 | -127 | 130 | 67 |
| 31 Dec 21 | 145 | -115 | 121 | 64 |
| 30 Sep 21 | 139 | -109 | 113 | 61 |
| 30 Jun 21 | 134 | -99 | 103 | 56 |
| 31 Mar 21 | 122 | -99 | 97 | 55 |
| 31 Dec 20 | 117 | -110 | 90 | 63 |
| 30 Sep 20 | 118 | -63 | 94 | 65 |
| 30 Jun 20 | 117 | -65 | 99 | 65 |
| 31 Mar 20 | 124 | -57 | 103 | 65 |
| 31 Dec 19 | 126 | -41 | 96 | 68 |
| 30 Sep 19 | 119 | -86 | 96 | 60 |
| 30 Jun 19 | 117 | -80 | 90 | 60 |
| 31 Mar 19 | 111 | -80 | 88 | 58 |
| 31 Dec 18 | 107 | -77 | 83 | 57 |
| 30 Sep 18 | 112 | -65 | 83 | 53 |
| 30 Jun 18 | 110 | -60 | 83 | 48 |
| 31 Mar 18 | 120 | -44 | 81 | 45 |
| 31 Dec 17 | 115 | -44 | 79 | 42 |
| 30 Sep 17 | 105 | -46 | 76 | 38 |
| 30 Jun 17 | 102 | -45 | 73 | 36 |
| 31 Mar 17 | 90 | -51 | 70 | 34 |
| 31 Dec 16 | 86 | -47 | 66 | 31 |
| 30 Sep 16 | 84 | -44 | 64 | 28 |
| 30 Jun 16 | 75 | -44 | 60 | 26 |
| 31 Mar 16 | 66 | -45 | 57 | 23 |
| 31 Dec 15 | 63 | -46 | 56 | 22 |
| 30 Sep 15 | 56 | -49 | 56 | 21 |
| 30 Jun 15 | 53 | -52 | 56 | 21 |
| 31 Mar 15 | 50 | -54 | 56 | 21 |
| 31 Dec 14 | 48 | -50 | 53 | 20 |
| 30 Sep 14 | 42 | -46 | 47 | 19 |
| 30 Jun 14 | 38 | -42 | 42 | 17 |
| 31 Mar 14 | 34 | -36 | 36 | 15 |
| 31 Dec 13 | 31 | -34 | 31 | 13 |
| 30 Sep 13 | 28 | -33 | 27 | 12 |
| 30 Jun 13 | 25 | -30 | 23 | 12 |
| 31 Mar 13 | 24 | -29 | 20 | 11 |
| 31 Dec 12 | 23 | -25 | 17 | 10 |
Kwaliteitswinsten: NSTG * is currently unprofitable.
Groeiende winstmarge: NSTG * is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: NSTG * is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.
Versnelling van de groei: Unable to compare NSTG *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: NSTG * is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-2.1%).
Rendement op eigen vermogen
Hoge ROE: NSTG *'s liabilities exceed its assets, so it is difficult to calculate its Return on Equity.